Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology.

RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...

This research delves into the association between anti-diabetic medications and cancer, exploring mechanisms beyond just ...

MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been published in the Journal of Health Economics and Outcomes ...